

Substitute for form 1449B/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
Sheet	of	1	Attorney Docket Number
COMPLETE IF KNOWN			
Application Number		10/568,168	
Filing Date		February 9, 2006	
First Named Inventor		Aurisicchio et al.	
Group Art Unit		1648	
Examiner Name		Peng, Bo	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.	
		de Kleijn, et al., "Biological therapy of colorectal cancer", European Journal of Cancer, 2002, Vol. 38, pp. 1016-1022.	
		Irvine, et al., "Characterization of Immunological Responses Using a CEA Recombinant Vaccinia Virus in Non-human Primates", Proceedings of the American Association for Cancer Research, Vol. 33, March 1992, pp. 334.	
		Rochlitz, "Gene therapy of cancer", Swiss Medical Weekly, 2001, Vol. 131, pp. 4-9	
		Verma, et al. "Gene therapy-promises, problems and prospects", Nature, 1997, Vol. 389, pp. 239-242	
		Vile, et al. "Cancer gene therapy: hard lessons and new courses", Gene Therapy, 2000, Vol. 7, pp. 2-8	
		Sequence Search Alignment for SEQ ID NOS: 2 and 8 with US 20060286114 (pp. 1-2)	
		Aurisicchio et al., "Preliminary Amendment Under 37 C.F.R. 1.115", Application No. 10/545,515, mailed August 15, 2005, 11 pages	
		Aurisicchio et al. , "Supplemental Preliminary Amendment Under 37 C.F.R. 1.115", Application No. 10/545,515 mailed October 6, 2006, 7 pages	
		Examiner L.A. Bristol, "Office Action: Restriction Requirement" Application No. 10/545, 515, mailed November 6, 2006, 7 pages	
		Aurisicchio et al., "Response to Restriction Requirement", Application No. 10/545,515, mailed November 16, 2006, 2 pages	
		Examiner L.A. Bristol,"Office Action" Application No. 10/545, 515, mailed January 11, 2007, 14 pages	
		Aurisicchio et al., "Amendment Under 37 C.F.R. 1.111", Application No. 10/545, 515, mailed April 5, 2007, 57 pages	
		Examiner L.A. Bristol, "Office Action" Application No. 10/545, 515, mailed July 17, 2007, 20 pages	
		Aurisicchio et al., "Amendment Under 37 C.F.R. 1.111" Application No. 10/545, 515, mailed October 17, 2007, 58 pages	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/28/2007